High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies

Gane, E. J.; Pianko, S.; Roberts, S. K.; Thompson, A. J.; Zeuzem, S.; Zuckerman, E.; Ari, Z. B.; Foster, G. R.; Agarwal, K.; Laursen, A. L.; Gerstoft, J.; Gao, W.; Huang, H.-C.; Fitzgerald, B.; Li, J. J.; Wan, S.; Dutko, F.; Nguyen, B.-Y. T.; Wahl, J.; Barr, E.; Butterton, J. R.; Esteban, R.

Published in

Elsevier, Journal of Hepatology, 2(64), p. S759

DOI: 10.1016/s0168-8278(16)01479-3

Tools

Export citation

Search in Google Scholar

High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies

Journal article published in 2016 by E. J. Gane, S. Pianko, S. K. Roberts, A. J. Thompson, S. Zeuzem, E. Zuckerman, Z. B. Ari, G. R. Foster, K. Agarwal

, A. L. Laursen, J. Gerstoft, W. Gao, H.-C. Huang, B. Fitzgerald, J. J. Li and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving forbidden

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies